<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041470</url>
  </required_header>
  <id_info>
    <org_study_id>18245</org_study_id>
    <nct_id>NCT00041470</nct_id>
  </id_info>
  <brief_title>Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial</brief_title>
  <official_title>Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this are:&#xD;
&#xD;
        -  To determine the highest doses of Taxol and Navelbine that we can safely give to&#xD;
           patients;&#xD;
&#xD;
        -  To determine what kind of side effects are caused by the combination of Taxol, Navelbine&#xD;
           and G-CSF;&#xD;
&#xD;
        -  To determine whether the combination of Taxol, Navelbine and G-CSF is more effective&#xD;
           than standard therapy in treating metastatic breast cancer and prolonging life;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complete response (CR) in advanced breast cancer is an important predictor of improved&#xD;
      survival. The largest experience reported with long-term follow-up in this regard is from&#xD;
      M.D. Anderson Hospital, with a median survival of 33 months and 5-year survival of 19% among&#xD;
      patients who achieved a CR with doxorubicin-based chemotherapy.19 We believe that our&#xD;
      institutional experience to date indicates that CR rates in excess of 20% can be achieved in&#xD;
      second-line chemotherapy from the combination of vinorelbine and a taxane, provided that&#xD;
      G-CSF is given. For the reasons outlined, we believe that dose density is likely to be&#xD;
      important for both classes of agents, but dose intensity may be most important for&#xD;
      vinorelbine. Both paclitaxel and docetaxel can be given on a weekly schedule with some&#xD;
      success, but it appears that myelosuppression is a more frequent dose-limiting toxicity on&#xD;
      this schedule for docetaxel. For the current trial, we therefore propose to study weekly&#xD;
      paclitaxel in combination with dose-intensive vinorelbine, utilizing continuous G-CSF support&#xD;
      as in our prior studies. We believe that starting doses of 60 mg/m2 for paclitaxel and 20&#xD;
      mg/m2 for vinorelbine will be well tolerated, but our experience to date, treating 3 patients&#xD;
      off study at these doses without G-CSF support, indicates that some will require G-CSF even&#xD;
      at this dose level: we observed grade 4 neutropenia in 2 of the 3. Our intention in this&#xD;
      trial is to determine the optimal dose of these two agents when continuous growth factor&#xD;
      support is provided. We will be starting at a ratio of 0.8 for vinorelbine and 0.75 for&#xD;
      paclitaxel (assuming 80 mg/m2/week as a &quot;full&quot; dose for the later agent).&#xD;
&#xD;
      It is now widely appreciated that patients with metastatic breast cancer whose tumors over&#xD;
      express HER-2-neu demonstrate benefit from the addition of trastuzumab (Herceptin) to a&#xD;
      chemotherapy program with paclitaxel as a single agent.20 Such patients will be allowed to&#xD;
      receive trastuzumab in the standard dose and schedule (4 mg/kg loading dose, then 2&#xD;
      mg/kg/week) given IV, in addition to paclitaxel and vinorelbine. Since trastuzumab does not&#xD;
      produce myelosuppression or neuropathy (the anticipated dose-limiting toxicities for&#xD;
      vinorelbine and paclitaxel, respectively), and neither of these agents combined separately&#xD;
      with trastuzumab produces unusual or severe new side effects, this should not affect the dose&#xD;
      escalation scheme for the chemotherapeutic agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor withdrew the study&#xD;
  </why_stopped>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Measure Response Rates, Time to Progression and Survival in Patients so Treated.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Measure the Qualitative and Quantitative Toxicity of This Regimen.</measure>
    <time_frame>&lt;=18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly paclitaxel, vinorelbine and GCSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.&#xD;
Paclitaxel weekly. Dose levels:&#xD;
50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2&#xD;
Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:&#xD;
20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2&#xD;
Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.&#xD;
G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.</description>
    <arm_group_label>Weekly paclitaxel, vinorelbine and GCSF</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.</description>
    <arm_group_label>Weekly paclitaxel, vinorelbine and GCSF</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.</description>
    <arm_group_label>Weekly paclitaxel, vinorelbine and GCSF</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.</description>
    <arm_group_label>Weekly paclitaxel, vinorelbine and GCSF</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PATIENT ELIGIBILITY&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has stage IV, microscopically-confirmed carcinoma of the breast with&#xD;
             histologic slides and/or blocks available for review.&#xD;
&#xD;
          -  Patient has had one or less prior regimens for metastatic disease. Prior paclitaxel by&#xD;
             3, 24 or 96-hour infusion is permitted as long as it did not result in any neuropathy.&#xD;
             Prior docetaxel on an every 3-week schedule is permitted.&#xD;
&#xD;
          -  Measurable (bidimensionally) or evaluable disease.&#xD;
&#xD;
          -  Age &gt; 18.&#xD;
&#xD;
          -  Karnofsky Performance Status &gt; 70% (ECOG, &lt; 2) at screen and on the first day of&#xD;
             treatment.&#xD;
&#xD;
          -  Life expectancy &gt; 16 weeks.&#xD;
&#xD;
          -  Prior irradiation is permitted, provided:&#xD;
&#xD;
          -  Prior irradiation does not exceed 25% of the estimated bone marrow volume. (See&#xD;
             Appendix I)&#xD;
&#xD;
          -  Measurable/evaluable disease must exist outside the radiation field OR there must be&#xD;
             histologic proof of progressive disease within a radiation field.&#xD;
&#xD;
          -  Informed consent must be obtained prior to registration.&#xD;
&#xD;
          -  Patients must be &gt; 2 weeks from prior surgery; &gt; 3 weeks from radiation therapy to the&#xD;
             pelvis, spine or long bones; &gt; 3 weeks from prior chemotherapy (&gt; 6 weeks for&#xD;
             mitomycin C or nitrosureas), or &gt; 2 weeks from prior hormonal therapy.&#xD;
&#xD;
          -  All patients must have placement of appropriate central venous access device.&#xD;
&#xD;
          -  Tumor HER2/neu expression must be determined prior to study enrollment. Assessment may&#xD;
             be by fluorescence in situ hydridization (FISH) assay or by immunohistochemistry&#xD;
             (ICC). If determination is intermediate by ICC, FISH must be performed. For enrollment&#xD;
             purposes, the phase I portion of the study will not discriminate based on HER2 status.&#xD;
             However, documentation of patients' HER2 status will be maintained and Herceptin will&#xD;
             be prescribed for all HER2 positive patients. The phase II portion of the study will&#xD;
             enroll 30 patients who are documented HER2 overexpressors and 30 patients who are&#xD;
             non-overexpressors.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Granulocytes &lt; 1,500/mm3.&#xD;
&#xD;
          -  Platelets &lt; 100,000/mm3.&#xD;
&#xD;
          -  Hemoglobin &lt; 9 gm/dl.&#xD;
&#xD;
          -  Creatinine &gt; 2.0 mg/dl.&#xD;
&#xD;
          -  Total bilirubin &gt; 2 mg/dl.&#xD;
&#xD;
          -  Visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung&#xD;
             metastases.&#xD;
&#xD;
          -  Medically unstable as judged by the patient's physician.&#xD;
&#xD;
          -  Pregnancy or lactation; failure to employ adequate contraception.&#xD;
&#xD;
          -  Uncontrolled CNS disease.&#xD;
&#xD;
          -  Pre-existing clinically significant peripheral neuropathy except for abnormalities due&#xD;
             to cancer.&#xD;
&#xD;
          -  Psychological, familial, sociological or geographical conditions which do not permit&#xD;
             weekly medical follow-up and compliance with the study protocol.&#xD;
&#xD;
          -  Prior therapy with vinorelbine or prior therapy with a taxane that resulted in&#xD;
             neuropathy.&#xD;
&#xD;
          -  Known hypersensitivity to E. coli-derived proteins, Filgrastim, or any component of&#xD;
             the product as Neupogen® is contraindicated in such subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie R. Gralow, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 9, 2002</study_first_submitted>
  <study_first_submitted_qc>July 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2002</study_first_posted>
  <results_first_submitted>March 23, 2017</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2017</results_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Julie Ruth Gralow</investigator_full_name>
    <investigator_title>Professor of Medicine, Medicine/Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paclitaxel, Vinorelbine, G-CSF, Herceptin - no Placebo</title>
          <description>Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease. Treatment continues until disease progression, toxicity or other reason to remove the patient from protocol treatment.&#xD;
Paclitaxel is administered weekly. Dose levels:&#xD;
50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2&#xD;
Vinorelbine (Navelbine) is administered one hour after paclitaxel, every week. Dose levels:&#xD;
20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2&#xD;
Patients whose tumors over express HER-2-neu and who meet the cardiac safety criteria will receive weekly Herceptin administered by intravenous infusion.&#xD;
Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.&#xD;
G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., is administered daily including the day of chemotherapy.&#xD;
Paclitaxel: 50 mg/m2 IV weekly. Treatment continues until progression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Loss of Funding</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I/II</title>
          <description>Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease. Treatment continues until disease progression, toxicity or other reason to remove the patient from protocol treatment.&#xD;
Paclitaxel is administered weekly. Dose levels:&#xD;
50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2&#xD;
Vinorelbine (Navelbine) is administered one hour after paclitaxel, every week. Dose levels:&#xD;
20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2&#xD;
Patients whose tumors over express HER-2-neu and who meet the cardiac safety criteria will receive weekly Herceptin administered by intravenous infusion.&#xD;
Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.&#xD;
G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., is administered daily including the day of chemotherapy.&#xD;
Paclitaxel: 50 mg/m2 IV weekly. Treatment continues until disease pr</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" lower_limit="27" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Participants</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Measure Response Rates, Time to Progression and Survival in Patients so Treated.</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weekly Paclitaxel, Vinorelbine and GCSF</title>
            <description>Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.&#xD;
Paclitaxel weekly. Dose levels:&#xD;
50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2&#xD;
Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:&#xD;
20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2&#xD;
Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.&#xD;
G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily&#xD;
Paclitaxel: 50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.&#xD;
Vinorelbine: 20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.&#xD;
Herceptin: 4 mg/kg IV loading dose day 1</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure Response Rates, Time to Progression and Survival in Patients so Treated.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Inevaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Measure the Qualitative and Quantitative Toxicity of This Regimen.</title>
        <time_frame>&lt;=18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weekly Paclitaxel, Vinorelbine and GCSF</title>
            <description>Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.&#xD;
Paclitaxel weekly. Dose levels:&#xD;
50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2&#xD;
Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:&#xD;
20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2&#xD;
Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.&#xD;
G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily&#xD;
Paclitaxel: 50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.&#xD;
Vinorelbine: 20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.&#xD;
Herceptin: 4 mg/kg IV loading dose day 1</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure the Qualitative and Quantitative Toxicity of This Regimen.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=Grade 3 Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Weekly Paclitaxel and Vinorelbine With GCSF Support</title>
          <description>Weekly paclitaxel (50 mg/m2 IV) and vinorelbine (20 mg/m2 IV) with daily G-CSF and Herceptin for patients with HER-2+ disease. Treatment until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.&#xD;
Paclitaxel administered weekly. Dose levels:&#xD;
50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2&#xD;
Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:&#xD;
20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2&#xD;
Patients who are HER-2+ and meet the cardiac safety criteria will receive weekly Herceptin administered by infusion.&#xD;
Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.&#xD;
G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., is administered daily including the day of chemotherapy.&#xD;
Paclitaxel: 50 mg/m2 IV weekly. Treatment continues until disease pr</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <description>Requiring total parenteral nutrition</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie Gralow, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-288-2053</phone>
      <email>pink@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

